United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback

United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback

Source: 
Endpoints
snippet: 

About three years after acquiring SteadyMed and its experimental pulmonary arterial hypertension drug Trevyent, United Therapeutics has decided to kick the program to the curb.

In an 8-K form filed with the SEC on Tuesday, United revealed that they are shutting down development of Trevyent after receiving feedback from the FDA last week.